Formulary Group work programme


Forthcoming submissions 2016

This list is indicative and may be subject to change.

Albiglutide (Eperzan®) - SMC 1024/15 - Formulary Group advice will be published by 2nd February 2016.  (Indication: Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control).

Atazanavir/cobicistat 300mg/105mg film coated tablets (Evotaz®) - SMC 1098/15 - Formulary Group advice will be published by 2nd February 2016.  (Indication: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir).

Docetaxel - FG1 392/15 - Formulary Group advice will be published by 2nd February 2016.

Dulaglutide (Trulicity®) - SMC 1110/15 - Formulary Group advice will be published by 2nd February 2016.  (Indication: in adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.)

DuoResp - FGA 008/15 - Formulary Group advice will be published by 2nd February 2016.

Fluticasone furoate/vilanterol (Relvar Ellipta®) - SMC 966/14 - Formulary Group advice will be published by 2nd February 2016.  (Indication: the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists).

Moviprep - FG1 388/15 - in progress. (Indication: bowel cleansing preparation).

Netupitant/palonosetron (Akynzeo®) - SMC 1109/15 - Formulary Group advice will be published by 2nd February 2016.  (Indication: in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy.

Sorafenib (Nexavar®) - SMC 482/08 - Formulary Group advice will be published by 2nd February 2016.  (Indication: the treatment of hepatocellular carcinoma).

Tolvaptan (Jinarc®) - SMC 1114/15 - Formulary Group advice will be published by 2nd February 2016. (Indication: to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease).

Ustekinumab (Stelara®) - SMC 1115/15 - Formulary Group advice will be published by 2nd February 2016.  (Indication: treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »